Metrics as of 10/17/2026, 08:54 AM (Berlin time), refresh in progress.
Immunome Stock
Immunome, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Clay Siegall
- Employees
- 247
- Market cap
- $1.9 B
- IPO
- 02/10/2020
Immunome, Inc. is a biotechnology company based in Bothell, United States, operating within the Healthcare sector. Founded in 2006, the company currently employs 247 employees and is listed on the NASDAQ, having gone public on October 2, 2020. The business model focuses on the discovery, design, development,…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Immunome stock: price history
1D
-5.3%
1W
-15.8%
1M
-29.8%
6M
-33.1%
YTD
-23.3%
1Y
-0.1%
2Y
+33.5%
5Y
-6.5%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~3% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Immunome
Analyst assessment of Immunome
PRICE TARGET LOW
US$24.00
CONSENSUS
US$33.00
MEDIAN
US$35.00
PRICE TARGET HIGH
US$37.00
0
STRONG BUY
13
BUY
0
HOLD
0
SELL
0
STRONG SELL
13
TOTAL · Buy
As of: 10/09/2026
Immunome stock metrics
P/E
-6.48
P/B
3.55
EV/EBITDA
-6.9
RETURN ON EQUITY
-13.9%
NET MARGIN
0.0%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
91.7%
FLOAT SHARES
108,213,117
AVG. DAILY VOLUME (30D)
1,395,028
Insider transactions (SEC)
Higgins Jack
Higgins Jack
Higgins Jack
Barchas Isaac
Barchas Isaac
Institutional holders
Comparable stocks
Frequently asked questions about Immunome stock
What does Immunome do?
Immunome, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Clay Siegall, the company employs around 247 people.
The IPO was on 02/10/2020; the stock trades on NASDAQ under the ticker IMNM.
What do analysts say about Immunome stock?
13 analysts rate the stock, the consensus is Buy (as of 10/09/2026).
The average price target is US$33.00, ranging from US$24.00 to US$37.00, with a median of US$35.00.
This is an external assessment, not a statement by Market Jury.
When does Immunome report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -3% stronger than usual.
Does Immunome pay a dividend?
No, Immunome currently does not pay a dividend.
Which stocks are comparable to Immunome?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Immunome stock analyzed?
Clicking "Analyze stock" lets five strategies assess Immunome against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.